Current applications of molecular cytogenetic technologies

Annals of Clinical and Laboratory Science

Volumn 27, Issue 1, 1997, Pages 47-56

  Mark, Hon Fong Louie ^a,d   Jenkins, Robert ^b   Miller, Wayne A ^c  

^a BROWN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c Prenatal Diagnostic Center   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; BREAST CANCER; CHROMOSOME 8; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DUPLICATION; HUMAN; HUMAN TISSUE; MOLECULAR GENETICS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SCREENING TEST;

BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CYTOGENETICS; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PLOIDIES; PRENATAL DIAGNOSIS; PROSTATIC NEOPLASMS; SEQUENCE DELETION;

EID: 0031024625     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Mark HFL. Fluorescent in situ hybridization as an adjunct to conventional cytogenetics. Ann Clin Lab Sci 1994;24:153-63.
2. Mark HFL, Chow B. Localization of the gene encoding the secretin receptor on human chromosome 2q by fluorescent in situ hybridization and chromosome morphometry. Genomics 1995;29:817-8.
3. Viegas-Pequignot E. In situ hybridization to chromosomes with biotinylated probes. In: Wilkinson EG, ed. In Situ Hybridization. Oxford: IRL Press, 1992.
4. Sandberg AA, Ture-Carel C. The cytogenetics of solid tumors: relation to diagnosis, classification and pathology. Cancer 1987;59:387-95.
5. Afify A, Bland KI, Mark HFL. Fluorescent in situ hybridization assessment of chromosome copy number in breast cancer. Breast Cancer Research and Treatment 1996;38:201-8.
6. Kapaun P, Kabisch H, Hold KR, Walter TA, Hegwisch S, Zander AR. A typical chronic myelogenous leukemia in a patient with trisomy 8 mosaicism syndrome. Ann Hematol 1993;66:57-8.
7. Micale MA. Defining the extent and nature of cytogenetic events in prostatic adenocarcinoma; Paraffin FISH vs. metaphase analysis. Cancer Genet Cytogenet 1993;69:7-12.
8. Persons DL. Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. Am J Pathol 1993; 142:733-41.
9. Bullerdiek J, Raebe G, Bartnitzke S, Boschen C, Schloot W. Structural rearrangements of chromosome 8 involving 8q12, a primary event in pleomorphic adenoma of the parotid gland. Genetica 1987;72:85-92.
10. Fletcher JA, Naeem R, Xiao S, Corson JM. Chromosome aberration in desmoid tumors; trisomy 8 may be a predictor of recurrence. Cancer Genet Cytogenet 1995;79:139-43.
11. Mark HFL, Ahearn J, Lathrop J. Constitutional trisomy 8 mosaicism and gestational trophoblastic disease. Cancer Genet Cytogenet 1995;80:150-4.
12. Bullerdiek J. Trisomy 8 as a recurrent clonal abnormality in breast cancer. Cancer Genet Cytogenet 1993;64:64-7.
13. Afify A and Mark HFL. (Manuscript accepted).
14. Gittes RF. Carcinoma of prostate. N Engl J Med 1991;324:236-45.
15. Shankey V, Kalioniemi O, Koslowski JM, Lieber MM, Mayall BH, Miller G, Smith GJ. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 1993;14:497-500.
16. Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987;59:788-94.
17. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986; 17:64-71.
18. McNeal JE, Alroy J, Leav I, Redwin EA, Freiha FS, Stamey TA. Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. Am J Clin Pathol 1988;90:23-32.
19. Quinn DB, Cho KR, Epstein JI. Relationship of severe dysplasia to stage B adenocarcinoma of prostate. Cancer 1990;65:2328-37.
20. Davidson D, Bostwick DG, Qian J, Wollan P, Osterling JE, Rudders RA, Siroky M, Stilmant M. Prostatic intraepithelial neoplasia is predictive of adenocarcinoma. J Urol 1995;154:1295-9.
21. Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 1993;24: 298-310.
22. Macoska JA, Micale MA, Sakr WA, Benson PD, Wolman SR. Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis. Genes, Chrom Cancer 1993;8:88-97.
23. Sakr WA, Macosk JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, Crissman JD. Allelic loss in locally metastatic, multisamples prostate cancer. Cancer Res 1994;54:3273-7.
24. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB. Potential markers for prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 1994;54:3574-9.
25. Effert PJ, Neubauer A, Walther PJ, Liu ET. Alterations of p53 gene are associated with the progression of a human prostate carcinoma. J Urol 1992;147:789-93.
26. Macoska JA, Powell IJ, Sakr WA, Lane M. Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate. J Urol 1992;147:1142-6.
27. Devilee P, Thierry RF, Kievits T, Kolluri R, Hopman AHN, Willard HF, Pearson PL, Cornelisse CJ. Detection of chromosome aneuploidy in interphase nuclei from human primary breast tumors using chromosome-specific repetitive DNA probes. Cancer Res 1988;48:5825-30.
28. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, Jenkins RB. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 1994; 54:3998-4002,
29. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, Jenkins RB. Frequent loss of heterozygosity at 7q31.1 in prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 1995;55:4114-9.
30. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ Hybridization. Cancer Res 1995;55:5408-14.
31. Qian J, Jenkins RB, Bostwick DG. Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Urology 1995;46:837-42.
32. 0) prostate cancer patients. Clin Cancer Res 1996 (in press).
33. Ledbetter DH. Microdeletion syndromes: FISH is responsible for the death of high resolution cytogenetics. The Genetic Viewpoint 1995;2:5-6.
34. Kuwano A, Ledbetter SA, Dobyns WB, Emanuel BS, Ledbetter DH. Detection of deletions and cryptic translocations in Miller-Dieker syndrome by in situ hybridization. Am J Hum Genet 1991;49:707-14.
35. Kuwano A, Mutirangura A, Dittrich B, Buiting K, Horsthemke B, Saitoh S, Niikawa N, Ledbetter SA, Greenberg F, Chinault AC. Molecular dissection of the Prader-Willi/Angelman syndrome region (15q11-13) by YAC cloning and FISH analysis, Hum Molec Genet 1992;1:417-25.
36. Driscoll DA, Salvin J, Sellinger B, Budarf ML, McDonald-McGinn DM, Zackai EH, Emanuel BS. Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: Implications for genetic counseling and prenatal diagnosis. J Med Genet 1993; 30:813-7.
37. Desmaze G, Scambler P, Prieur M, Halford S, Sidi D, Le Deist F, Aurias A. Routine diagnosis of DiGeorge syndrome by fluorescence in situ hybridization. Human Genet 1993;90:663-5.
38. Ward BE, Gersen SL, Carelli MP, et al. Rapid prenatal diagnosis of chromosomal aneuploidies by fluorescence in situ hybridization: Clinical experience with 4,500 specimens. Am J Hum Genet 1993;52:854-65.
39. Philip J, Bryndorf T, Christensen B. Prenatal aneuploidy detection in interphase cells by fluorescence in situ hybridization (FISH). Prenat Diagn 1994;14: 1203-16.
40. Schwartz S. Efficacy and applicability of interphase fluorescence in situ hybridization for prenatal diagnosis. Am J Hum Genet 1993;52:851-3.
41. Evans MI, Ebrahim SAD, Berry SM, et al. Fluorescent in situ hybridization utilization for high risk prenatal diagnosis; a trade-off among speed, expense and inherent limitations of chromosome specific probes. Am J Obstet Gynecol 1994;171:1055-7.
42. Christensen B, Bryndorf T, Philip J, et al. Prenatal diagnosis by in situ hybridization on uncultured amniocytes: reduced sensitivity and potential risk of misdiagnosis in blood-stained samples. Prenat Diagn 1993;13:581-7.
43. Clark BA, Kenney K, Olson S. The need to reevaluate trisomy screening for advance maternal age in prenatal diagnosis. Am J Obstet Gynecol 1993;168:812-6.
44. Hume RF, Kilmer-Ernst P, Wolfe HM, et al. Prenatal cytogenetic abnormalities: Correlations of structural rearrangements and ultrasonographically detected fetal anomalies. Am J Obstet Gynecol 1995;173: 1334-6.
45. Isada NB, Hume RF, Reichler A, et al. Fluorescent in situ hybridization (FISH) and second trimester sonographic anomalies: uses and limitations. Fetal Diagn Ther 1994;9:367-70.
46. Hanna JS, Neu RL, Lockwood DH. Prenatal cytogenetic results from cases referred for 44 different types of abnormal ultrasound findings. Prenat Diagn 1996; 16:109-16.
47. Rizzo N, Pittalis MC, Pilu G, et al. Distribution of abnormal karyotypes among malformed fetuses detected by ultrasound throughout gestation. Prenat Diagn 1996;16:159-164.
48. American College of Medical Genetics: Prenatal interphase fluorescence in situ hybridization (FISH) policy statement. Am J Hum Genet 1993;53:526-7.
49. New England Regional Genetics Group: Fluorescent in situ hybridization policy statement. The Genetics Resource 1992;6:56.
50. Lubs HA, Elsas LJ, Tharapel AT, et al. Position statement on interphase in situ hybridization prental diagnosis. Am J Med Genet 1993;46:478.
51. Mark HFL, Kelly T, Watson MS, Hoeltge G, Miller WA, Beauregard L. Current issues of personnel and laboratory practices in genetic testing. J Med Genetics 1995;32:780-6.
52. Mark HFL, Watson MS. Evolving standards of practice for clinical cytogenetics. Rhode Island Medicine 1994;77:375-6.
53. American College of Medical Genetics (ACMG). Standards and guidelines: Clinical genetics laboratories. ACMG Laboratory Practice Committee, 1994:1-34.